Mylan’s Biogenerics Strategy: Build Standards From Europe, Be Financially Cautious
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firm is counting on Global Biologics Head Patrick Vink’s experience as Sandoz biopharma head to lead the firm into the follow-on biologics marketplace.